- Home
- ATLCP vs INM Comparison
ATLCP vs INM Comparison
Compare ATLCP & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLCP
- INM
- Stock Information
- Founded
- ATLCP N/A
- INM 1981
- Country
- ATLCP United States
- INM Canada
- Employees
- ATLCP 417
- INM N/A
- Industry
- ATLCP Finance: Consumer Services
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- ATLCP Finance
- INM Health Care
- Exchange
- ATLCP Nasdaq
- INM Nasdaq
- Market Cap
- ATLCP N/A
- INM 5.1M
- IPO Year
- ATLCP N/A
- INM N/A
- Fundamental
- Price
- ATLCP $24.20
- INM $2.12
- Analyst Decision
- ATLCP
- INM
- Analyst Count
- ATLCP 0
- INM 0
- Target Price
- ATLCP N/A
- INM N/A
- AVG Volume (30 Days)
- ATLCP N/A
- INM 122.5K
- Earning Date
- ATLCP N/A
- INM 11-13-2025
- Dividend Yield
- ATLCP N/A
- INM N/A
- EPS Growth
- ATLCP N/A
- INM N/A
- EPS
- ATLCP N/A
- INM N/A
- Revenue
- ATLCP N/A
- INM $4,942,633.00
- Revenue This Year
- ATLCP N/A
- INM N/A
- Revenue Next Year
- ATLCP N/A
- INM N/A
- P/E Ratio
- ATLCP N/A
- INM N/A
- Revenue Growth
- ATLCP N/A
- INM 7.50
- 52 Week Low
- ATLCP N/A
- INM $1.72
- 52 Week High
- ATLCP N/A
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- ATLCP 52.22
- INM 45.83
- Support Level
- ATLCP $24.06
- INM $2.07
- Resistance Level
- ATLCP $24.20
- INM $2.26
- Average True Range (ATR)
- ATLCP 0.31
- INM 0.14
- MACD
- ATLCP -0.09
- INM -0.01
- Stochastic Oscillator
- ATLCP 53.78
- INM 23.92
About ATLCP Atlanticus Holdings Corporation 7.625% Series B Cumulative Perpetual Preferred Stock no par value per share
Atlanticus Holdings Corp invests in the financial services industry. It provides various credit and related financial services and products to or associated with the financially underserved consumer credit market. The operating business segments are the Credit as a Service (CaaS) and the Auto Finance segment. It generates maximum revenue from the Credit as a Service segment.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.